<p>The burgeoning field of epitranscriptomics -modifications of RNA molecules that do not alter the underlying RNA sequence but affect gene expression- has unveiled m⁶A as a pivotal modulator of RNA fate, with profound implications for alternative splicing and cancer progression. This review synthesizes current evidence delineating the molecular mechanisms by which m⁶A deposition influences spliceosomal dynamics and RNA processing. Central to this process is the coordinated action of m⁶A “writers,” “erasers,” and binding proteins (“readers”), which collectively dictate transcriptome diversity through precise modulation of splicing decisions. Aberrant m⁶A modifications have been increasingly correlated with dysregulated splicing patterns that contribute to oncogenic transformation, tumor heterogeneity, and the emergence of aggressive cancer phenotypes. By integrating findings from recent studies, this article highlights the critical interplay between epitranscriptomic regulation and the alternative splicing machinery, underscoring how these interactions drive pathophysiological processes in cancer. Furthermore, the review explores emerging therapeutic opportunities targeting the m⁶A regulatory network, calling attention to its potential as both a prognostic biomarker and a novel intervention point in precision oncology. Through a comprehensive examination of the current literature, this analysis provides valuable insights into the role of m⁶A in sculpting the cancer transcriptome, offering a robust framework for future research endeavors in the field of cancer biology and therapeutic innovation.</p>